- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05276232
Detection of Cannabis Impairment With ISBRG's SpotLight-THC
Subjects will participate in a 2-visit study protocol in which they will be administered cannabis of pre-determined concentrations and asked to complete a simulated drive in a driving simulator. Subjects will be scanned on two SpotLight-THC (Alpha and Beta iterations) devices and peripheral venous whole blood will be collected from subjects for analysis on up to four occasions on each visit.
The purpose of the investigation will be to determine whether the SpotLight-THC device is a reliable measure of THC impairment at the roadside, with an objective to identify a unique blood analyte architecture for THC impairment using near infrared light and machine learning.
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Rose A Schmitt, B.S.
- Phone Number: 319-335-4666
- Email: rose-potter@uiowa.edu
Study Contact Backup
- Name: Timothy L Brown, Ph.D.
- Phone Number: 319-335-4785
- Email: timothy-l-brown@uiowa.edu
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- National Advanced Driving Simulator
-
Contact:
- Rose A Schmitt, B.S.
- Phone Number: 319-335-4666
- Email: rose-potter@uiowa.edu
-
Contact:
- Timothy L Brown, Ph.D.
- Phone Number: 319-335-4785
- Email: timothy-l-brown@uiowa.edu
-
Principal Investigator:
- Timothy L Brown, Ph.D.
-
Sub-Investigator:
- Gary R Gaffney, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged at least 18 years old
- Must self-report use of cannabis at least once a month
- Has held a valid driver's license at least 12 months
- Must be willing to abstain from using cannabis and alcohol for 24 hours prior to each session
- Must be willing to abstain from all other drugs not medically required for duration of the study (beginning 24 hours prior to the screening visit)
- Must be able to drive without special or non-standard equipment
- Must be able to meet study time commitment
- Provides written and informed consent
Exclusion Criteria:
- Diagnosis of severe medical or psychiatric condition (as judged by study physician)
- Evidence of substance use disorder as reflected by total scores on DUDIT and AUDIT
- Regular user of medication that may affect cognitive functioning and/or driver performance (e.g., antidepressants, benzodiazepines, stimulants, opioids) as judged by study physician
- Family history of schizophrenia or other psychotic disorder (or taking medications for such)
- Pregnant or test positive for pregnancy, looking to become pregnant, or breastfeeding
- Respiratory or pulmonary disorder that would negatively affect ability to inhale and hold the cannabis dose
- Recent (past 6 months) head injury or stroke, or current symptoms from prior head injury or stroke
- History of heart disease, angina, heart attack, heart surgery, or myocardial infarction (or taking medications for such)
- Untreated/Untreatable vision or auditory issues (because testing currently requires both senses)
- History of suicidal behaviors in past two years
- Excessive tobacco use (more than 10 cigarettes a day or 3 or more cigars or pipes per day)
- Excessive caffeine use (6 or more servings per day)
- Excessive alcohol (14 or more drinks per week)
- Regular use of pain medications other than OTC
- Use of prescription drugs not prescribed to them or illicit drugs other than cannabis
- History of substance abuse or substance addiction
- Expressed interest in or participation in drug abuse treatment in past 60 days
- Currently diagnosed cannabis use disorder
- History of negative reaction to cannabis
- Extreme scarring on fingertips that prevents use of the device
- Participation in night shift work
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Baseline followed by 5-10% THC Validation
|
Cannabis vapor is produced from 500mg, approximately 5-10% High dose bulk cannabis plant material, 30-37.5 mg THC
|
Experimental: Baseline followed by 5-10% THC Verification
|
Cannabis vapor is produced from 500mg, approximately 5-10% High dose bulk cannabis plant material, 30-37.5 mg THC
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Acute Subjective Response to Cannabis Score
Time Frame: At baseline, 20, 30, 60, 90, 120 and 180 minutes
|
The total score of the true responses (true/false scale, minimum score is 0 with a maximum score of 12).
A higher score indicates greater drug effect.
Used to determine subjective level of drug effect.
|
At baseline, 20, 30, 60, 90, 120 and 180 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Standard Deviation of Lateral Position (SDLP) - Undistracted
Time Frame: Over a 20 minute drive conducted at 30, 90 and 180 minutes post dose
|
The ability to keep the vehicle straight in the lane and the corresponding data is presented from a rural drive without any secondary tasks relative to the 20 minute baseline drive pre dose.
|
Over a 20 minute drive conducted at 30, 90 and 180 minutes post dose
|
Standard Deviation of Lateral Position (SDLP) - Distracted
Time Frame: Over a 20 minute drive conducted at 30, 90 and 180 minutes post dose
|
The ability to keep the vehicle straight in the lane and the corresponding data is presented from a rural drive while engaged in a secondary task relative to the 20 minute baseline drive while engaged in the same task pre dose.
|
Over a 20 minute drive conducted at 30, 90 and 180 minutes post dose
|
Blood Delta-9-THC
Time Frame: At baseline, 20, 90, and 180 minutes
|
THC concentration levels of Delta-9-THC in whole blood.
|
At baseline, 20, 90, and 180 minutes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Timothy L Brown, Ph.D., National Advanced Driving Simulator
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202108451
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis
-
Centre hospitalier de l'Université de Montréal...RecruitingCannabis | Cannabis Dependence | Cannabis Use | Cannabis Smoking | Cannabis Use, UnspecifiedCanada
-
Elias DakwarRecruitingAddiction | Cannabis Dependence | Cannabis Use | Substance Abuse | Cannabis Abuse | Cannabis Use DisorderUnited States
-
University College, LondonMedical Research Council; InvicroCompletedCannabis | Cannabis Dependence | Cannabis Use | CBD | Adolescent Development | THC | Marijuana | Cannabis IntoxicationUnited Kingdom
-
University of WashingtonNational Institute on Drug Abuse (NIDA)CompletedCannabis Dependence | Cannabis Abuse
-
The University of Tennessee, KnoxvilleColorado State UniversityActive, not recruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedCannabis Dependence | Cannabis AbuseFrance
-
University of VermontDartmouth College; Rutgers UniversityCompletedCannabis Use | Tolerance | Cannabis WithdrawalUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Yale UniversityRobert E. Leet and Clara Guthrie Patterson Trust Mentored Research AwardRecruitingCannabis | Cannabis Use | Cannabis AbuseUnited States
Clinical Trials on Cannabis(THC) inhaled
-
Advanced Brain Monitoring, Inc.University of IowaCompletedAlcohol Intoxication | Driving Under the Influence | Marijuana IntoxicationUnited States
-
University of California, San DiegoCenter for Medicinal Cannabis ResearchNot yet recruiting
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Not yet recruiting
-
University of California, San DiegoCenter for Medicinal Cannabis ResearchRecruitingHIV | Cannabis UseUnited States
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
Germans Trias i Pujol HospitalIstituto Superiore di Sanità; Fundació Institut Germans Trias i PujolCompletedHealthy Subjects | Cannabis UseSpain
-
Jamie BurrActive, not recruitingCannabis | Cardiovascular Risk FactorCanada
-
Brown UniversityTerminatedRheumatoid Arthritis | Psoriatic ArthritisUnited States
-
Fenix Innovation GroupMonash Health; Neurotech InternationalNot yet recruitingAutism Spectrum DisorderAustralia
-
Parc de Salut MarTerminated